Federica Marchesi

List of Publications by Year
in descending order

63	7,594	126708 33	128067 60
papers	citations	h-index	g-index

64	64	64	13274
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tumour-associated macrophages as treatment targets in oncology. Nature Reviews Clinical Oncology, 2017, 14, 399-416.	12.5	2,667
2	Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood, 2005, 106, 419-427.	0.6	544
3	Increased Survival, Proliferation, and Migration in Metastatic Human Pancreatic Tumor Cells Expressing Functional CXCR4. Cancer Research, 2004, 64, 8420-8427.	0.4	313
4	Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14825-14830.	3.3	311
5	Occurrence of Tertiary Lymphoid Tissue Is Associated with T-Cell Infiltration and Predicts Better Prognosis in Early-Stage Colorectal Cancers. Clinical Cancer Research, 2014, 20, 2147-2158.	3.2	264
6	Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine Production. Cancer Research, 2005, 65, 2964-2971.	0.4	263
7	Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis. Cytokine and Growth Factor Reviews, 2010, 21, 77-82.	3.2	215
8	Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut, 2016, 65, 1710-1720.	6.1	193
9	Chemokines in cancer related inflammation. Experimental Cell Research, 2011, 317, 664-673.	1.2	191
10	Inflammation and cancer: Breast cancer as a prototype. Breast, 2007, 16, 27-33.	0.9	181
11	Cancerâ€promoting tumorâ€associated macrophages: New vistas and open questions. European Journal of Immunology, 2011, 41, 2522-2525.	1.6	179
12	Inflammation-mediated promotion of invasion and metastasis. Cancer and Metastasis Reviews, 2010, 29, 243-248.	2.7	177
13	Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. OncoImmunology, 2016, 5, e1085147.	2.1	169
14	The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Research, 2003, 63, 7451-61.	0.4	154
15	The Chemokine Receptor CX3CR1 Is Involved in the Neural Tropism and Malignant Behavior of Pancreatic Ductal Adenocarcinoma. Cancer Research, 2008, 68, 9060-9069.	0.4	153
16	Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1954-1961.	3.3	122
17	Tumor-associated myeloid cells: diversity and therapeutic targeting. Cellular and Molecular Immunology, 2021, 18, 566-578.	4.8	100
18	Macrophage morphology correlates with single-cell diversity and prognosis in colorectal liver metastasis. Journal of Experimental Medicine, 2020, 217, .	4.2	99

#	Article	IF	Citations
19	The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. Journal of Clinical Investigation, 2010, 120, 3969-3978.	3.9	96
20	Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. Journal of Neuroimmunology, 2010, 224, 39-44.	1.1	90
21	Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. OncoImmunology, 2017, 6, e1342918.	2.1	90
22	CXCL13 expression in the gut promotes accumulation of IL-22-producing lymphoid tissue-inducer cells, and formation of isolated lymphoid follicles. Mucosal Immunology, 2009, 2, 486-494.	2.7	70
23	Tertiary Intratumor Lymphoid Tissue in Colo-Rectal Cancer. Cancers, 2012, 4, 1-10.	1.7	68
24	Differential Effects of Immunosuppressive Drugs on Chemokine Receptor CCR7 in Human Monocyte-Derived Dendritic Cells: Selective Upregulation by Rapamycin. Transplantation, 2006, 82, 826-834.	0.5	62
25	Immune cells: plastic players along colorectal cancer progression. Journal of Cellular and Molecular Medicine, 2013, 17, 1088-1095.	1.6	62
26	A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 236-247.	1.4	59
27	Tumor-Associated Macrophages and Dendritic Cells as Prototypic Type II Polarized Myeloid Populations. Tumori, 2003, 89, 459-468.	0.6	54
28	Presence of Twist1-Positive Neoplastic Cells in the Stroma ofÂChromosome-Unstable Colorectal Tumors. Gastroenterology, 2013, 145, 647-657.e15.	0.6	49
29	Inflammation and prostate cancer: friends or foe?. Inflammation Research, 2015, 64, 275-286.	1.6	48
30	Macrophages in Colorectal Cancer Liver Metastases. Cancers, 2019, 11, 633.	1.7	47
31	Prognostic significance of tumor-associated macrophages: past, present and future. Seminars in Immunology, 2020, 48, 101408.	2.7	40
32	IL-10 and Macrophages Orchestrate Gut Homeostasis. Immunity, 2014, 40, 637-639.	6.6	38
33	Linking Inflammation Reactions to Cancer: Novel Targets for Therapeutic Strategies. Advances in Experimental Medicine and Biology, 2008, 610, 112-127.	0.8	37
34	The Fractalkine-Receptor Axis Improves Human Colorectal Cancer Prognosis by Limiting Tumor Metastatic Dissemination. Journal of Immunology, 2016, 196, 902-914.	0.4	35
35	Expression of the Chemokine Binding Protein M3 Promotes Marked Changes in the Accumulation of Specific Leukocytes Subsets Within the Intestine. Gastroenterology, 2009, 137, 1006-1018.e3.	0.6	30
36	Circulating Inflammatory Mediators as Potential Prognostic Markers of Human Colorectal Cancer. PLoS ONE, 2016, 11, e0148186.	1.1	30

#	Article	IF	Citations
37	Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model. Oncotarget, 2016, 7, 43010-43026.	0.8	29
38	Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition. OncoImmunology, 2018, 7, e1388485.	2.1	28
39	Early expression of the fractalkine receptor CX3CR1 in pancreatic carcinogenesis. British Journal of Cancer, 2013, 109, 2424-2433.	2.9	26
40	Tertiary Lymphoid Tissue in the Tumor Microenvironment: From Its Occurrence to Immunotherapeutic Implications. International Reviews of Immunology, 2015, 34, 123-133.	1.5	26
41	Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells. Cancer Immunology Research, 2020, 8, 493-505.	1.6	26
42	Macrophages at the crossroads of anticancer strategies. Frontiers in Bioscience - Landmark, 2019, 24, 1271-1283.	3.0	20
43	Manipulation of Glucose Availability to Boost Cancer Immunotherapies. Cancers, 2020, 12, 2940.	1.7	15
44	Attenuation of TNF-driven murine ileitis by intestinal expression of the viral immunomodulator CrmD. Mucosal Immunology, 2010, 3, 633-644.	2.7	14
45	Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancer. Nuclear Medicine Communications, 2018, 39, 636-644.	0.5	14
46	Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System. Current Pharmaceutical Design, 2012, 18, 2432-2438.	0.9	14
47	The Role of Chemokines and their Receptors in Tumor Progression and Invasion: Potential New Targets of Biological Therapy. Current Cancer Therapy Reviews, 2005, 1, 81-92.	0.2	13
48	Tertiary lymphoid tissue. OncoImmunology, 2014, 3, e28850.	2.1	9
49	The neuro-immune axis in cancer: Relevance of the peripheral nervous system to the disease. Immunology Letters, 2020, 227, 60-65.	1.1	9
50	Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes. International Journal of Molecular Sciences, 2021, 22, 5246.	1.8	9
51	Development of a Deep-Learning Pipeline to Recognize and Characterize Macrophages in Colo-Rectal Liver Metastasis. Cancers, 2021, 13, 3313.	1.7	8
52	Immune mediators as potential diagnostic tools for colorectal cancer: from experimental rationale to early clinical evidence. Expert Review of Molecular Diagnostics, 2014, 14, 387-399.	1.5	6
53	Histopathological and Immune Prognostic Factors in Colo-Rectal Liver Metastases. Cancers, 2021, 13, 1075.	1.7	5
54	Oncogenic KRAS-Induced Protein Signature in the Tumor Secretome Identifies Laminin-C2 and Pentraxin-3 as Useful Biomarkers for the Early Diagnosis of Pancreatic Cancer. Cancers, 2022, 14, 2653.	1.7	5

#	Article	IF	Citations
55	Hepatobiliary surgeons meet immunologists: the case of colorectal liver metastases patients. Hepatobiliary Surgery and Nutrition, 2019, 8, 370-377.	0.7	4
56	Immune infiltrating cells in duodenal cancers. Journal of Translational Medicine, 2020, 18, 340.	1.8	3
57	Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness. Expert Review of Anticancer Therapy, 2014, 14, 1219-1228.	1.1	1
58	Immunotherapy in hepatobiliary tumors: search for the missing pieces of the puzzle. Hepatobiliary Surgery and Nutrition, 2020, 9, 86-88.	0.7	1
59	Liver metastases â€œsiphonâ€•off immunotherapy response. Hepatobiliary Surgery and Nutrition, 2021, 10, 526-529.	0.7	1
60	Prognostic Value of Innate and Adaptive Immunity in Cancers. , 2015, , 275-284.		1
61	Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma. Journal of Visualized Experiments, 2020, , .	0.2	1
62	The Immune Landscape in a Long-Term Survival Pancreatic Adenocarcinoma Patient Highly Responsive to a Multidisciplinary Approach With Chemo-Radio Treatments. Pancreas, 2021, 50, e76-e78.	0.5	0
63	A topology perspective on macrophages in melanoma metastasis. Cell Reports Medicine, 2022, 3, 100643.	3.3	0